New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
复制标题
DOI：
10.1186/bcr927
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
Hidalgo M
中科院分区：
文献类型：
--
作者：
Carraway H;Hidalgo M
哺乳动物雷帕霉素靶蛋白（mTOR）是细胞磷脂酰肌醇3-激酶（PI 3 K）通路的丝氨酸-苏氨酸激酶成员，参与转录和翻译调控等多种生物学功能。mTOR是PI 3 K/Akt信号通路的下游介质，在细胞存活中起关键作用。在乳腺癌中，该途径可被膜受体激活，包括HER（或ErbB）家族的生长因子受体、胰岛素样生长因子受体和雌激素受体。有证据表明Akt促进乳腺癌细胞存活和对化疗、曲妥珠单抗和他莫昔芬的抗性。雷帕霉素是一种特异性mTOR拮抗剂，靶向该途径并阻断下游信号传导元件，导致细胞周期停滞在G1期。用mTOR拮抗剂靶向Akt/PI 3 K通路可以增加乳腺癌治疗的疗效。
Mammalian target of rapamycin (mTOR) is a serine-threonine kinase member of the cellular phosphatidylinositol 3-kinase (PI3K) pathway, which is involved in multiple biologic functions such as transcriptional and translational control. mTOR is a downstream mediator in the PI3K/Akt signaling pathway and plays a critical role in cell survival. In breast cancer this pathway can be activated by membrane receptors, including the HER (or ErbB) family of growth factor receptors, the insulin-like growth factor receptor, and the estrogen receptor. There is evidence suggesting that Akt promotes breast cancer cell survival and resistance to chemotherapy, trastuzumab, and tamoxifen. Rapamycin is a specific mTOR antagonist that targets this pathway and blocks the downstream signaling elements, resulting in cell cycle arrest in the G1 phase. Targeting the Akt/PI3K pathway with mTOR antagonists may increase the therapeutic efficacy of breast cancer therapy.
登录
查看更多内容
影响因子：
--
作者：
Cui, XJ;Zhang, P;Lee, AV
通讯作者：
Lee, AV
影响因子：
8
作者：
Knuefermann, C;Lu, Y;Fan, Z
通讯作者：
Fan, Z
影响因子：
1.7
作者：
Miller, FE
通讯作者：
Miller, FE
影响因子：
45.3
作者：
Atkins, MB;Hidalgo, M;Sherman, ML
通讯作者：
Sherman, ML
影响因子：
3.3
作者：
ENG, CP;SEHGAL, SN;VEZINA, C
通讯作者：
VEZINA, C